The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer

Journal of Urology

Volumn 164, Issue 3 I, 2000, Pages 685-689

  Solsona, E ^a   Iborra, I ^a   Dumont, R ^a   Rubio Briones, J ^a   Casanova, J ^a   Almenar, S ^a  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

Administration; Bladder; Bladder neoplasms; Disease progression; Intravesical

Indexed keywords

BCG VACCINE; DOXORUBICIN; MITOMYCIN C;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER RISK; CARCINOMA IN SITU; CYSTECTOMY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 0033888947     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)67281-3     Document Type: Article

References (22)

1. Pansadoro, V., Emiliozzi, P., Defidio, L. et al: Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results. J Urol, 154:2054, 1995
2. Cookson, M. S., Herr, H. W., Zhang, Z.-F. et al: The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol, 158: 62, 1997
3. Solsona, E., Iborra, I., Ricós, J. L. et al: Impact on cause-specific survival of secondary cystectomy in patients with high risk superficial bladder cancer. Eur Urol, 35: 38, abstract, 1999
4. Amling, C. L., Thrasher, J. B., Frazier, H. A. et al: Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol, 151: 31, 1994
5. Hrouda, D., Ogden, C., Morris, S. B. et al.: Multiple frequent recurrences in superficial transitional cell carcinoma of the bladder: is survival compromised by a conservative management strategy? Br J Urol, 79: 726, 1997
6. Bono, A. V., Benvenuti, C., Damiano, G. et al: Results of transurethral resection and intravesical doxorubicin prophylaxis in patients with T1G3 bladder cancer. Urology, 44: 329, 1994
7. Coplen, D. E., Marcus, M. D., Myers, J. A. et al: Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. J Urol, 144: 652, 1990
8. Herr, H. W., Badalament, R. A., Amato, D. A. et al: Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol, 141: 22, 1989
9. Angulo, J. G., Lopez, J. I. Grignon, D. J. et al: Muscularis mucosa differentiates two populations with different prognosis in stage Tl bladder cancer. Urology, 45: 47, 1995
10. Zellweger, T., Went, P., Sauter, G. et al: Prognostic relevance of the depth of invasion in stage T1 bladder carcinoma. J Urol, suppl., 159:143, abstract 544, 1998
11. Mellon, K. Wright, C., Kelly, P. et al: Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol, part 2, 153: 919, 1995
12. Sarkis, A., Dalbagni, G., Cordon-Cardo, C. et al: Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol, 152: 388, 1994
13. WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J Urol, 161: 792. 1999
14. Solsona, E., Iborra, I., Ricós, J. V. et al: Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long-term followup of a prospective study. J Urol, 159: 95, 1998
15. Solsona, E., Iborra, I., Ricós, J. V. et al: Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications. J Urol, 155: 895, 1996
16. Fitzpatrick, J. M., West, A. B., Butler, M. R. et al: Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol, 135:920, 1986
17. Merz, V. W., Marth, D., Kraft, R. et al: Analysis of early failures after intravesical instillation therapy with bacillus Calmette-Guerin for carcinoma in situ of the bladder. Br J Urol, 75:180, 1995
18. Herr, H. W.: Progression of stage T1 ladder tumors after intravesical bacillus Calmette-Guerin. J Urol, 145: 40, 1991
19. Herr, H. W.: Risk-benefit ratio of intravesical BCG: indications for cystectomy after initial conservative approach. In: Optimal Therapies for Patients With High-Risk Superficial Bladder Cancer: Controversy and Consensus. Edited by A. Böhle and D. Jocham. Oxford: Medicine Pub. Foundation, vol. 37, pp. 97-102, 1997
20. Engelhardt, P. F., Simak, R., Riedl, C. R. et al: Is a second look TUR-B in patients with superficial bladder cancer necessary?. Eur Urol, 35: 24, abstract, 1999
21. Haaff, E. O., Dresner, S. M., Ratliff, T. L. et al: Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder. J Urol, 136: 820, 1986
22. Bretton, P. R., Herr, H. W., Kimmel, M. et al: The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin. J Urol, 143: 710, 1990